Semaglutide May Reduce Alcohol Use Disorder, Lancet Study Finds
A new clinical trial published in The Lancet suggests that semaglutide—best known as a GLP-1 receptor agonist for obesity and type 2 diabetes—may also help reduce alcohol consumption in patients with Alcohol Use Disorder (AUD).
The findings are significant because current treatment options for AUD remain limited. Only three medications are currently approved by the U.S. FDA for treating alcohol dependence, despite alcohol misuse contributing to approximately 5% of global deaths annually.
The study indicates that semaglutide may simultaneously address two major public health problems: obesity and compulsive alcohol use.
🧠 Why Researchers Are Studying GLP-1 Drugs for Addiction #
Alcohol Use Disorder is a chronic relapsing brain disorder characterized by:
- Compulsive alcohol consumption
- Loss of control over drinking behavior
- High relapse rates
Recent preclinical and early human studies have suggested that GLP-1 receptor agonists may influence reward pathways and craving-related behaviors in the brain.
This has led researchers to investigate whether medications such as semaglutide could reduce:
- Alcohol craving
- Heavy drinking frequency
- Overall alcohol intake
while also producing metabolic benefits.
🔬 Clinical Trial Design #
The study was a:
- Randomized
- Double-blind
- Placebo-controlled
- Single-center clinical trial
conducted over 26 weeks at the Mental Health Center Copenhagen in Denmark.
Participant Profile #
- Total participants: 108
- Age range: 18–70 years
- Diagnosed with moderate-to-severe AUD
- Also met criteria for obesity:
- BMI ≥ 30 kg/m²
Alcohol Consumption Criteria #
Participants met the following daily intake thresholds:
- Men: ≥60 g alcohol/day
- Women: ≥48 g alcohol/day
Treatment Groups #
Semaglutide Group #
- Weekly subcutaneous injections
- Dose escalation:
- Started at 0.25 mg
- Increased every 4 weeks
- Maximum maintenance dose: 2.4 mg
Placebo Group #
- Received matching saline injections
Behavioral Therapy #
All participants also received standardized cognitive behavioral therapy (CBT), including:
- Drinking motivation support
- Cognitive restructuring
- Relapse prevention strategies
Each session lasted at least 45 minutes.
No nutritional counseling was included during the trial.
📊 Primary Endpoint Results #
The primary endpoint measured the change in the percentage of heavy-drinking days (HDDs) from baseline to week 26 using the Timeline Followback (TLFB) method.
Baseline Characteristics #
Before treatment:
- Average heavy-drinking days: 17.2 per month
- Average alcohol intake over 30 days: 2,200.9 g
Heavy-Drinking Day Reduction #
Semaglutide Group #
- Reduced heavy-drinking days by:
- 41.1 percentage points
Placebo Group #
- Reduced heavy-drinking days by:
- 26.4 percentage points
Treatment Difference #
- Estimated difference:
- -13.7 percentage points
- Statistical significance:
- 95% CI: -22.0 to -5.4
- P = 0.0015
These findings indicate a clinically meaningful reduction in problematic drinking behavior.
🍷 Secondary Outcome Improvements #
Semaglutide also showed advantages across multiple secondary endpoints.
Total Alcohol Consumption #
Over a 30-day period:
-
Semaglutide group:
- Average reduction: 1,550.2 g
-
Placebo group:
- Average reduction: 1,025.9 g
Alcohol Intake Per Drinking Day #
-
Semaglutide:
- Reduced by 3.5 standard units
-
Placebo:
- Reduced by 2.3 standard units
Alcohol Craving #
Measured using the Pennsylvania Alcohol Craving Scale (PACS):
-
Semaglutide:
- Average reduction: 9.2 points
-
Placebo:
- Average reduction: 6.1 points
Weight Loss #
-
Semaglutide group:
- Average weight loss: 11.2 kg
-
Placebo group:
- Average weight loss: 2.2 kg
The dual metabolic and behavioral effects make semaglutide particularly notable in this population.
⚠️ Safety and Tolerability #
The safety profile was generally consistent with previously known GLP-1 receptor agonist effects.
Most Common Adverse Effects #
- Nausea
- Gastrointestinal discomfort
- Mild-to-moderate digestive symptoms
Most side effects were:
- Temporary
- Non-severe
- More common in the semaglutide group
No major unexpected safety concerns were reported during the trial period.
🌍 Clinical and Public Health Implications #
The study provides emerging evidence that GLP-1 receptor agonists may have applications beyond metabolic disease.
Potential Advantages #
- Simultaneous treatment of obesity and AUD
- Reduction in alcohol craving and intake
- Weekly dosing improves adherence potential
- May expand limited pharmacological options for addiction treatment
Given the large global overlap between obesity and problematic alcohol use, the implications could be substantial.
🔚 Conclusion #
The Lancet trial adds growing evidence that semaglutide may help reduce heavy alcohol consumption while also supporting meaningful weight loss in patients with Alcohol Use Disorder and obesity.
Although the results are promising, researchers caution that larger and longer-term studies are still necessary before GLP-1 receptor agonists can become standard therapy for alcohol addiction.
If future research confirms these findings, semaglutide and related GLP-1 drugs could represent a major shift in the treatment landscape for both metabolic disease and addiction medicine.